Antidepressant Drugs Market By Type (Serotonin and Noradrenaline Reuptake Inhibitors (SNRIs), Selective Serotonin Reuptake Inhibitors (SSRIs), Tricyclic Antidepressants (TCAs), Monoamine Oxidase Inhibitors (MAOIs), Noradrenaline and Specific Serotoninergic Antidepressants (NASSAs); By Mode of Administration (Tablets and Capsules, Liquids, Injections, Inhalation, Others) ; By End-Users (Hospitals and Clinics, Pharmacies, Urgent Care Centers, Research Institutes, Others); By Disorder Type (Major and Minor Depression, Obsessive Compulsive Disorder, Generalized Anxiety , Posttraumatic Stress (PTSD), Social Anxiety , Agitation and Stress , Bipolar Disorder, Others); By Region (U.S., Canada, Mexico, Rest of North America, The UK, France, Germany, Italy, Spain, Nordic Countries (Denmark, Finland, Iceland, Sweden, Norway), Benelux Union (Belgium, the Netherlands, Luxembourg), Rest of Europe, China, Japan, India, New Zealand, Australia, South Korea, Southeast Asia (Indonesia, Thailand, Malaysia, Singapore, Rest of Southeast Asia), Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of Middle East & Africa, Brazil, Argentina, Rest of Latin America) – Global Insights, Growth, Size, Comparative Analysis, Trends and Forecast, 2020 – 2028

Report ID :AMI-719 | Category : Healthcare | Published Date : November, 2020 | Pages : 402 | Format :PDF

Industry Trends

The life of human beings have become highly complex in recent times, and remarks such as life was less complicated years back are often heard. Change in lifestyle, especially in cities and towns, is being seen around the globe. Urbanization efforts by government bodies and higher income offered in urban locations can be cited as a major reason for the migration of people towards cities and towns. Job-related stress, especially in developing and developed countries, is a leading cause of depression. Furthermore, there is an increased chance of depression in individuals who have got a family history of depression, experienced childhood trauma, a less active frontal lobe in the brain and consumption of drugs, amongst others. In case of drug use, studies show that around 21% of individuals who have used banned substances (drugs) experience depression at some stage in their life, which in turn is increasing the demand of antidepressant drugs market. Common symptoms of depression include mood swings, loss in appetite, irregular sleep patterns, suicidal thoughts, fatigue, etc. Based on the World Health Organization (WHO) statistics, depression affects more than 264 million human beings globally. It is also the leading cause of disability and contributes significantly towards the global disease burden. Government bodies in countries like India, China, US, the UK, France, etc., and world organizations, are increasingly focussing on providing effective treatments to combat the rise in cases of depression. The WHO, for example, has formulated a mental health awareness program called as mental health Gap Action Programme (mhGAP) which aims at providing medical care to those individuals who are affected by depression. Several treatment methods have been proven effective in the treatment of depression. Medical practitioners recommend psychological methods like behavioural therapy, interpersonal psychotherapy, and cognitive behavioural therapy (CBT). In other cases, antidepressant drugs are provided to the patients, mainly through prescriptions. Selective serotonin reuptake inhibitors (SSRIs) and tricyclic antidepressants (TCAs) are commonly prescribed by healthcare professionals. These drugs are effective in cases of moderate to severe depression. In the UK, for instance, around 10.4% individuals who seek medical treatment for depression are prescribed antidepressant drugs. Furthermore, there has been a considerable increase in the number of individuals seeking medical help for depression, as the stigma associated with the disease is decreasing globally. The rise in awareness amongst individuals regarding depression, coupled with the effectiveness of antidepressants in the treatment of the mental disease is leading to the growth of the global antidepressant drugs market.

Concerns regarding the side effects associated with antidepressants, coupled with the regulatory compliance for the manufacture of antidepressant drug is hindering the growth of the global antidepressant drugs market. In the case of selective serotonin reuptake inhibitors (SSRIs) and serotonin-noradrenaline reuptake inhibitors (SNRIs), for instance, the United Kingdom National Health Service states that side effects like increased anxiety, agitation, indigestion, dizziness, low sex drive, etc., can be seen during the initial months of antidepressant intake. Moreover, a health condition called serotonin syndrome is a potentially serious side effect associated with SSRI and SNRIs. These occur when individuals consume antidepressants along with drugs or substances that raise the serotonin levels in the brain. Periodic consultation with healthcare professionals regarding the effectiveness of the medication is of utmost importance in the case of antidepressants, since drug overdose and addiction can also be seen in certain cases. Furthermore, antidepressant drugs are not recommended for mild cases of depression, mainly because of these side effects. Higher awareness regarding the use of antidepressants, and efforts to reduce side effects in individuals will help in the growth of the global antidepressant drugs market in the coming years.

The COVID-19 pandemic has impacted the lives of numerous individuals across regions. Lockdown measures imposed in countries like Italy, France, India, etc., forced the individuals to stay indoors to curb the spread of the virus. Moreover, the economy has taken a severe hit, and jobs have been lost due to the pandemic. In India, for instance, studies show that around 4.1 million young adults have been laid off from work as a result of COVID-19. Concerns regarding job safety and lack of socialization amongst individuals is raising the number of individuals who are affected by depression. Studies show that in the U.S., for instance, there was a three-fold increase in depression symptoms in adults during the pandemic. Furthermore, the use of antidepressants for the treatment of COVID-19 patients is also being studied by researchers in Europe. Fluoxetine, a standard antidepressant drug, was found to reduce the replication of SARS-CoV-2 virus by the virologists and chemists at the University of Würzburg, Germany. These factors suggest that the COVID-19 pandemic is expected to have a positive impact on the global antidepressant drugs market.

In terms of revenue, global antidepressant drugs market was valued at US$ 24148.76 Mn in 2019 and is anticipated to grow at a CAGR of 12.13% over the forecast period (2020 – 2028). The study analyses the market in terms of revenue across all the major regions, which have been bifurcated into countries.

Global Antidepressant Drugs Market Revenue & Forecast, (US$ Million), 2015 – 2028

Type Outlook:

Selective Serotonin Reuptake Inhibitors (SSRIs) are the most commonly prescribed type of antidepressants. Serotonin and Noradrenaline Reuptake Inhibitors (SNRIs) and Tricyclic Antidepressants (TCAs) are also prescribed by health professionals, depending on the severity of depression. SNRIs are mainly used to treat severe cases of depression. They help in raising levels of serotonin and norepinephrine, which are neurotransmitters that determine mood stabilization in human beings. Some examples of SNRIs include venlafaxine (Effexor) and desvenlafaxine (Pristiq), duloxetine (Cymbalta), etc. As compared to SNRIs, SSRIs have fewer side effects, and are used to treat a broad range of illnesses. They are responsible for reducing the absorption of serotonin in the brain. They mainly affect on serotonin, leaving the other neurotransmitters unharmed. Some of the commonly prescribed SSRIs are scitalopram (Lexapro), fluoxetine (Prozac, Sarafem), ertraline (Zoloft), amongst others. Due to the fewer side effects and its ability to treat depression of varying magnitude, SSRIs accounted for a significant share in the global antidepressant drugs market in 2018.

Region Outlook:

Based on the regions, North America accounted for the highest share in the global antidepressant drugs market in 2018. Rising cases of depression, coupled with the presence of prominent antidepressant drug manufacturers like Novartis, Sanofi, Abbot, etc., can be cited as a major reason for this. Companies in North America are also innovating on treating depression based on various causes. Massachusetts-based Sage Therapeutics, for instance, is researching on a new drug that is postpartum depression. The drug, SAGE-547, is based on allopregnanolone, which is a neuroactive metabolite of progesterone that plays a crucial role in the reproductive system in females. Such factors are aiding for the growth of antidepressant drugs market.

Competitive Landscape

The report provides both, qualitative and quantitative research of antidepressant drugs market, as well as provides comprehensive insights and development methods adopted by the key contenders. The report also offers extensive research on the key players in this market and details on the competitiveness of these players. Key business strategies such as mergers and acquisitions (M&A), affiliations, collaborations, and contracts adopted by these major market participants are also recognized and analysed in the report. For each company, the report studies their global presence, competitors, service offerings and specification amongst others.

Some of the players operating in the antidepressant drugs market are Abbot, AbbVie, AstraZeneca, Eli Lilly and Company, F. Hoffmann-La Roche Ltd, GlaxoSmithKline plc., H. Lundbeck A/S, Janssen Pharmaceuticals, Inc., Lupin Pharmaceuticals, Inc., Merck & Co., Inc., Novartis AG, Pfizer Inc., sanofi-aventis U.S. LLC, Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd, amongst others.

Global Antidepressant Drugs Market:

By Type
- Serotonin and Noradrenaline Reuptake Inhibitors (Snris)
- Selective Serotonin Reuptake Inhibitors (Ssris)
- Tricyclic Antidepressants (Tcas)
- Monoamine Oxidase Inhibitors (Maois)
- Noradrenaline and Specific Serotoninergic Antidepressants (Nassas)
By Mode of Administration
- Tablets and Capsules
- Liquids
- Injections
- Inhalation
- Others
By End-Users
- Hospitals and Clinics
- Pharmacies
- Urgent Care Centers
- Research Institutes
- Others
By Disorder Type
- Major and Minor Depression
- Obsessive Compulsive Disorder
- Generalized Anxiety
- Posttraumatic Stress (PTSD)
- Social Anxiety
- Agitation and Stress
- Bipolar Disorder
- Others

By Region

North America
U.S
Canada
Mexico
Rest of North America
Europe
France
The UK
Spain
Germany
Italy
Nordic Countries
Denmark
Finland
Iceland
Sweden
Norway
Benelux Union
Belgium
The Netherlands
Luxembourg
Rest of Europe
Asia Pacific
China
Japan
India
New Zealand
Australia
South Korea
Southeast Asia
Indonesia
Thailand
Malaysia
Singapore
Rest of Southeast Asia
Rest of Asia Pacific
Middle East and Africa
Saudi Arabia
UAE
Egypt
Kuwait
South Africa
Rest of Middle East & Africa
Latin America
Brazil
Argentina
Rest of Latin America

Table of Contents

1. Market Scope

1.1. Market Segmentation

1.2. Years Considered

1.2.1. Historic Years: 2013 - 2018

1.2.2. Base Year: 2019

1.2.3. Forecast Years: 2020 – 2028

2. Key Target Audiences

3. Research Methodology

3.1. Primary Research

3.1.1. Research Questionnaire

3.1.2. Global Percentage Breakdown

3.1.3. Primary Interviews: Key Opinion Leaders (KOLs)

3.2. Secondary Research

3.2.1. Paid Databases

3.2.2. Secondary Sources

3.3. Market Size Estimates

3.3.1. Top-Down Approach

3.3.2. Bottom-Up Approach

3.4. Data Triangulation Methodology

3.5. Research Assumptions

4. Recommendations and Insights from AMI’s Perspective**

5. Holistic Overview of Antidepressant Drugs Market

6. Market Synopsis: Antidepressant Drugs Market

7. Antidepressant Drugs Market Analysis: Qualitative Perspective

7.1. Introduction

7.1.1. Product Definition

7.1.2. Industry Development

7.2. Market Dynamics

7.2.1. Drivers

7.2.2. Restraints

7.2.3. Opportunities

7.3. Trends in Antidepressant Drugs Market

7.4. Market Determinants Radar Chart

7.5. Macro-Economic and Micro-Economic Indicators: Antidepressant Drugs Market

7.6. Porter’s Five Force Analysis

7.7. Impact of Covid-19 on Antidepressant Drugs Market

8. Global Antidepressant Drugs Market Analysis and Forecasts, 2020 – 2028

8.1. Overview

8.1.1. Global Antidepressant Drugs Market Revenue (US$ Mn)

8.2. Global Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By Type

8.2.1. Serotonin and Noradrenaline Reuptake Inhibitors (SNRIs)

8.2.1.1. Definition

8.2.1.2. Market Estimation and Penetration, 2013 – 2019

8.2.1.3. Market Forecast, 2020 – 2028

8.2.1.4. Compound Annual Growth Rate (CAGR)

8.2.1.5. Regional Bifurcation

8.2.1.5.1. North America

8.2.1.5.1.1. Market Estimation, 2013 – 2019

8.2.1.5.1.2. Market Forecast, 2020 – 2028

8.2.1.5.2. Europe

8.2.1.5.2.1. Market Estimation, 2013 – 2019

8.2.1.5.2.2. Market Forecast, 2020 – 2028

8.2.1.5.3. Asia Pacific

8.2.1.5.3.1. Market Estimation, 2013 – 2019

8.2.1.5.3.2. Market Forecast, 2020 – 2028

8.2.1.5.4. Middle East and Africa

8.2.1.5.4.1. Market Estimation, 2013 – 2019

8.2.1.5.4.2. Market Forecast, 2020 – 2028

8.2.1.5.5. Latin America

8.2.1.5.5.1. Market Estimation, 2013 – 2019

8.2.1.5.5.2. Market Forecast, 2020 – 2028

8.2.2. Selective Serotonin Reuptake Inhibitors (SSRIs)

8.2.2.1. Definition

8.2.2.2. Market Estimation and Penetration, 2013 – 2019

8.2.2.3. Market Forecast, 2020 – 2028

8.2.2.4. Compound Annual Growth Rate (CAGR)

8.2.2.5. Regional Bifurcation

8.2.2.5.1. North America

8.2.2.5.1.1. Market Estimation, 2013 – 2019

8.2.2.5.1.2. Market Forecast, 2020 – 2028

8.2.2.5.2. Europe

8.2.2.5.2.1. Market Estimation, 2013 – 2019

8.2.2.5.2.2. Market Forecast, 2020 – 2028

8.2.2.5.3. Asia Pacific

8.2.2.5.3.1. Market Estimation, 2013 – 2019

8.2.2.5.3.2. Market Forecast, 2020 – 2028

8.2.2.5.4. Middle East and Africa

8.2.2.5.4.1. Market Estimation, 2013 – 2019

8.2.2.5.4.2. Market Forecast, 2020 – 2028

8.2.2.5.5. Latin America

8.2.2.5.5.1. Market Estimation, 2013 – 2019

8.2.2.5.5.2. Market Forecast, 2020 – 2028

8.2.3. Tricyclic Antidepressants (TCAs)

8.2.3.1. Definition

8.2.3.2. Market Estimation and Penetration, 2013 – 2019

8.2.3.3. Market Forecast, 2020 – 2028

8.2.3.4. Compound Annual Growth Rate (CAGR)

8.2.3.5. Regional Bifurcation

8.2.3.5.1. North America

8.2.3.5.1.1. Market Estimation, 2013 – 2019

8.2.3.5.1.2. Market Forecast, 2020 – 2028

8.2.3.5.2. Europe

8.2.3.5.2.1. Market Estimation, 2013 – 2019

8.2.3.5.2.2. Market Forecast, 2020 – 2028

8.2.3.5.3. Asia Pacific

8.2.3.5.3.1. Market Estimation, 2013 – 2019

8.2.3.5.3.2. Market Forecast, 2020 – 2028

8.2.3.5.4. Middle East and Africa

8.2.3.5.4.1. Market Estimation, 2013 – 2019

8.2.3.5.4.2. Market Forecast, 2020 – 2028

8.2.3.5.5. Latin America

8.2.3.5.5.1. Market Estimation, 2013 – 2019

8.2.3.5.5.2. Market Forecast, 2020 – 2028

8.2.4. Monoamine Oxidase Inhibitors (MAOIs)

8.2.4.1. Definition

8.2.4.2. Market Estimation and Penetration, 2013 – 2019

8.2.4.3. Market Forecast, 2020 – 2028

8.2.4.4. Compound Annual Growth Rate (CAGR)

8.2.4.5. Regional Bifurcation

8.2.4.5.1. North America

8.2.4.5.1.1. Market Estimation, 2013 – 2019

8.2.4.5.1.2. Market Forecast, 2020 – 2028

8.2.4.5.2. Europe

8.2.4.5.2.1. Market Estimation, 2013 – 2019

8.2.4.5.2.2. Market Forecast, 2020 – 2028

8.2.4.5.3. Asia Pacific

8.2.4.5.3.1. Market Estimation, 2013 – 2019

8.2.4.5.3.2. Market Forecast, 2020 – 2028

8.2.4.5.4. Middle East and Africa

8.2.4.5.4.1. Market Estimation, 2013 – 2019

8.2.4.5.4.2. Market Forecast, 2020 – 2028

8.2.4.5.5. Latin America

8.2.4.5.5.1. Market Estimation, 2013 – 2019

8.2.4.5.5.2. Market Forecast, 2020 – 2028

8.2.5. Noradrenaline and Specific Serotoninergic Antidepressants (NaSSAs)

8.2.5.1. Definition

8.2.5.2. Market Estimation and Penetration, 2013 – 2019

8.2.5.3. Market Forecast, 2020 – 2028

8.2.5.4. Compound Annual Growth Rate (CAGR)

8.2.5.5. Regional Bifurcation

8.2.5.5.1. North America

8.2.5.5.1.1. Market Estimation, 2013 – 2019

8.2.5.5.1.2. Market Forecast, 2020 – 2028

8.2.5.5.2. Europe

8.2.5.5.2.1. Market Estimation, 2013 – 2019

8.2.5.5.2.2. Market Forecast, 2020 – 2028

8.2.5.5.3. Asia Pacific

8.2.5.5.3.1. Market Estimation, 2013 – 2019

8.2.5.5.3.2. Market Forecast, 2020 – 2028

8.2.5.5.4. Middle East and Africa

8.2.5.5.4.1. Market Estimation, 2013 – 2019

8.2.5.5.4.2. Market Forecast, 2020 – 2028

8.2.5.5.5. Latin America

8.2.5.5.5.1. Market Estimation, 2013 – 2019

8.2.5.5.5.2. Market Forecast, 2020 – 2028

8.3. Key Segment for Channeling Investments

8.3.1. By Type

9. Global Antidepressant Drugs Market Analysis and Forecasts, 2020 – 2028

9.1. Overview

9.2. Global Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By Mode of Administration

9.2.1. Tablets and Capsules

9.2.1.1. Definition

9.2.1.2. Market Estimation and Penetration, 2013 – 2019

9.2.1.3. Market Forecast, 2020 – 2028

9.2.1.4. Compound Annual Growth Rate (CAGR)

9.2.1.5. Regional Bifurcation

9.2.1.5.1. North America

9.2.1.5.1.1. Market Estimation, 2013 – 2019

9.2.1.5.1.2. Market Forecast, 2020 – 2028

9.2.1.5.2. Europe

9.2.1.5.2.1. Market Estimation, 2013 – 2019

9.2.1.5.2.2. Market Forecast, 2020 – 2028

9.2.1.5.3. Asia Pacific

9.2.1.5.3.1. Market Estimation, 2013 – 2019

9.2.1.5.3.2. Market Forecast, 2020 – 2028

9.2.1.5.4. Middle East and Africa

9.2.1.5.4.1. Market Estimation, 2013 – 2019

9.2.1.5.4.2. Market Forecast, 2020 – 2028

9.2.1.5.5. Latin America

9.2.1.5.5.1. Market Estimation, 2013 – 2019

9.2.1.5.5.2. Market Forecast, 2020 – 2028

9.2.2. Liquids

9.2.2.1. Definition

9.2.2.2. Market Estimation and Penetration, 2013 – 2019

9.2.2.3. Market Forecast, 2020 – 2028

9.2.2.4. Compound Annual Growth Rate (CAGR)

9.2.2.5. Regional Bifurcation

9.2.2.5.1. North America

9.2.2.5.1.1. Market Estimation, 2013 – 2019

9.2.2.5.1.2. Market Forecast, 2020 – 2028

9.2.2.5.2. Europe

9.2.2.5.2.1. Market Estimation, 2013 – 2019

9.2.2.5.2.2. Market Forecast, 2020 – 2028

9.2.2.5.3. Asia Pacific

9.2.2.5.3.1. Market Estimation, 2013 – 2019

9.2.2.5.3.2. Market Forecast, 2020 – 2028

9.2.2.5.4. Middle East and Africa

9.2.2.5.4.1. Market Estimation, 2013 – 2019

9.2.2.5.4.2. Market Forecast, 2020 – 2028

9.2.2.5.5. Latin America

9.2.2.5.5.1. Market Estimation, 2013 – 2019

9.2.2.5.5.2. Market Forecast, 2020 – 2028

9.2.3. Injections

9.2.3.1. Definition

9.2.3.2. Market Estimation and Penetration, 2013 – 2019

9.2.3.3. Market Forecast, 2020 – 2028

9.2.3.4. Compound Annual Growth Rate (CAGR)

9.2.3.5. Regional Bifurcation

9.2.3.5.1. North America

9.2.3.5.1.1. Market Estimation, 2013 – 2019

9.2.3.5.1.2. Market Forecast, 2020 – 2028

9.2.3.5.2. Europe

9.2.3.5.2.1. Market Estimation, 2013 – 2019

9.2.3.5.2.2. Market Forecast, 2020 – 2028

9.2.3.5.3. Asia Pacific

9.2.3.5.3.1. Market Estimation, 2013 – 2019

9.2.3.5.3.2. Market Forecast, 2020 – 2028

9.2.3.5.4. Middle East and Africa

9.2.3.5.4.1. Market Estimation, 2013 – 2019

9.2.3.5.4.2. Market Forecast, 2020 – 2028

9.2.3.5.5. Latin America

9.2.3.5.5.1. Market Estimation, 2013 – 2019

9.2.3.5.5.2. Market Forecast, 2020 – 2028

9.2.4. Inhalation

9.2.4.1. Definition

9.2.4.2. Market Estimation and Penetration, 2013 – 2019

9.2.4.3. Market Forecast, 2020 – 2028

9.2.4.4. Compound Annual Growth Rate (CAGR)

9.2.4.5. Regional Bifurcation

9.2.4.5.1. North America

9.2.4.5.1.1. Market Estimation, 2013 – 2019

9.2.4.5.1.2. Market Forecast, 2020 – 2028

9.2.4.5.2. Europe

9.2.4.5.2.1. Market Estimation, 2013 – 2019

9.2.4.5.2.2. Market Forecast, 2020 – 2028

9.2.4.5.3. Asia Pacific

9.2.4.5.3.1. Market Estimation, 2013 – 2019

9.2.4.5.3.2. Market Forecast, 2020 – 2028

9.2.4.5.4. Middle East and Africa

9.2.4.5.4.1. Market Estimation, 2013 – 2019

9.2.4.5.4.2. Market Forecast, 2020 – 2028

9.2.4.5.5. Latin America

9.2.4.5.5.1. Market Estimation, 2013 – 2019

9.2.4.5.5.2. Market Forecast, 2020 – 2028

9.2.5. Others

9.2.5.1. Definition

9.2.5.2. Market Estimation and Penetration, 2013 – 2019

9.2.5.3. Market Forecast, 2020 – 2028

9.2.5.4. Compound Annual Growth Rate (CAGR)

9.2.5.5. Regional Bifurcation

9.2.5.5.1. North America

9.2.5.5.1.1. Market Estimation, 2013 – 2019

9.2.5.5.1.2. Market Forecast, 2020 – 2028

9.2.5.5.2. Europe

9.2.5.5.2.1. Market Estimation, 2013 – 2019

9.2.5.5.2.2. Market Forecast, 2020 – 2028

9.2.5.5.3. Asia Pacific

9.2.5.5.3.1. Market Estimation, 2013 – 2019

9.2.5.5.3.2. Market Forecast, 2020 – 2028

9.2.5.5.4. Middle East and Africa

9.2.5.5.4.1. Market Estimation, 2013 – 2019

9.2.5.5.4.2. Market Forecast, 2020 – 2028

9.2.5.5.5. Latin America

9.2.5.5.5.1. Market Estimation, 2013 – 2019

9.2.5.5.5.2. Market Forecast, 2020 – 2028

9.3. Key Segment for Channeling Investments

9.3.1. By Mode of Administration

10. Global Antidepressant Drugs Market Analysis and Forecasts, 2020 – 2028

10.1. Overview

10.2. Global Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By End-Users

10.2.1. Hospitals and Clinics

10.2.1.1. Definition

10.2.1.2. Market Estimation and Penetration, 2013 – 2019

10.2.1.3. Market Forecast, 2020 – 2028

10.2.1.4. Compound Annual Growth Rate (CAGR)

10.2.1.5. Regional Bifurcation

10.2.1.5.1. North America

10.2.1.5.1.1. Market Estimation, 2013 – 2019

10.2.1.5.1.2. Market Forecast, 2020 – 2028

10.2.1.5.2. Europe

10.2.1.5.2.1. Market Estimation, 2013 – 2019

10.2.1.5.2.2. Market Forecast, 2020 – 2028

10.2.1.5.3. Asia Pacific

10.2.1.5.3.1. Market Estimation, 2013 – 2019

10.2.1.5.3.2. Market Forecast, 2020 – 2028

10.2.1.5.4. Middle East and Africa

10.2.1.5.4.1. Market Estimation, 2013 – 2019

10.2.1.5.4.2. Market Forecast, 2020 – 2028

10.2.1.5.5. Latin America

10.2.1.5.5.1. Market Estimation, 2013 – 2019

10.2.1.5.5.2. Market Forecast, 2020 – 2028

10.2.2. Pharmacies

10.2.2.1. Definition

10.2.2.2. Market Estimation and Penetration, 2013 – 2019

10.2.2.3. Market Forecast, 2020 – 2028

10.2.2.4. Compound Annual Growth Rate (CAGR)

10.2.2.5. Regional Bifurcation

10.2.2.5.1. North America

10.2.2.5.1.1. Market Estimation, 2013 – 2019

10.2.2.5.1.2. Market Forecast, 2020 – 2028

10.2.2.5.2. Europe

10.2.2.5.2.1. Market Estimation, 2013 – 2019

10.2.2.5.2.2. Market Forecast, 2020 – 2028

10.2.2.5.3. Asia Pacific

10.2.2.5.3.1. Market Estimation, 2013 – 2019

10.2.2.5.3.2. Market Forecast, 2020 – 2028

10.2.2.5.4. Middle East and Africa

10.2.2.5.4.1. Market Estimation, 2013 – 2019

10.2.2.5.4.2. Market Forecast, 2020 – 2028

10.2.2.5.5. Latin America

10.2.2.5.5.1. Market Estimation, 2013 – 2019

10.2.2.5.5.2. Market Forecast, 2020 – 2028

10.2.3. Urgent Care Centers

10.2.3.1. Definition

10.2.3.2. Market Estimation and Penetration, 2013 – 2019

10.2.3.3. Market Forecast, 2020 – 2028

10.2.3.4. Compound Annual Growth Rate (CAGR)

10.2.3.5. Regional Bifurcation

10.2.3.5.1. North America

10.2.3.5.1.1. Market Estimation, 2013 – 2019

10.2.3.5.1.2. Market Forecast, 2020 – 2028

10.2.3.5.2. Europe

10.2.3.5.2.1. Market Estimation, 2013 – 2019

10.2.3.5.2.2. Market Forecast, 2020 – 2028

10.2.3.5.3. Asia Pacific

10.2.3.5.3.1. Market Estimation, 2013 – 2019

10.2.3.5.3.2. Market Forecast, 2020 – 2028

10.2.3.5.4. Middle East and Africa

10.2.3.5.4.1. Market Estimation, 2013 – 2019

10.2.3.5.4.2. Market Forecast, 2020 – 2028

10.2.3.5.5. Latin America

10.2.3.5.5.1. Market Estimation, 2013 – 2019

10.2.3.5.5.2. Market Forecast, 2020 – 2028

10.2.4. Research Institutes

10.2.4.1. Definition

10.2.4.2. Market Estimation and Penetration, 2013 – 2019

10.2.4.3. Market Forecast, 2020 – 2028

10.2.4.4. Compound Annual Growth Rate (CAGR)

10.2.4.5. Regional Bifurcation

10.2.4.5.1. North America

10.2.4.5.1.1. Market Estimation, 2013 – 2019

10.2.4.5.1.2. Market Forecast, 2020 – 2028

10.2.4.5.2. Europe

10.2.4.5.2.1. Market Estimation, 2013 – 2019

10.2.4.5.2.2. Market Forecast, 2020 – 2028

10.2.4.5.3. Asia Pacific

10.2.4.5.3.1. Market Estimation, 2013 – 2019

10.2.4.5.3.2. Market Forecast, 2020 – 2028

10.2.4.5.4. Middle East and Africa

10.2.4.5.4.1. Market Estimation, 2013 – 2019

10.2.4.5.4.2. Market Forecast, 2020 – 2028

10.2.4.5.5. Latin America

10.2.4.5.5.1. Market Estimation, 2013 – 2019

10.2.4.5.5.2. Market Forecast, 2020 – 2028

10.2.5. Others

10.2.5.1. Definition

10.2.5.2. Market Estimation and Penetration, 2013 – 2019

10.2.5.3. Market Forecast, 2020 – 2028

10.2.5.4. Compound Annual Growth Rate (CAGR)

10.2.5.5. Regional Bifurcation

10.2.5.5.1. North America

10.2.5.5.1.1. Market Estimation, 2013 – 2019

10.2.5.5.1.2. Market Forecast, 2020 – 2028

10.2.5.5.2. Europe

10.2.5.5.2.1. Market Estimation, 2013 – 2019

10.2.5.5.2.2. Market Forecast, 2020 – 2028

10.2.5.5.3. Asia Pacific

10.2.5.5.3.1. Market Estimation, 2013 – 2019

10.2.5.5.3.2. Market Forecast, 2020 – 2028

10.2.5.5.4. Middle East and Africa

10.2.5.5.4.1. Market Estimation, 2013 – 2019

10.2.5.5.4.2. Market Forecast, 2020 – 2028

10.2.5.5.5. Latin America

10.2.5.5.5.1. Market Estimation, 2013 – 2019

10.2.5.5.5.2. Market Forecast, 2020 – 2028

10.3. Key Segment for Channeling Investments

10.3.1. By End-Users

11. Global Antidepressant Drugs Market Analysis and Forecasts, 2020 – 2028

11.1. Overview

11.2. Global Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By Disorder Type

11.2.1. Major and Minor Depression

11.2.1.1. Definition

11.2.1.2. Market Estimation and Penetration, 2013 – 2019

11.2.1.3. Market Forecast, 2020 – 2028

11.2.1.4. Compound Annual Growth Rate (CAGR)

11.2.1.5. Regional Bifurcation

11.2.1.5.1. North America

11.2.1.5.1.1. Market Estimation, 2013 – 2019

11.2.1.5.1.2. Market Forecast, 2020 – 2028

11.2.1.5.2. Europe

11.2.1.5.2.1. Market Estimation, 2013 – 2019

11.2.1.5.2.2. Market Forecast, 2020 – 2028

11.2.1.5.3. Asia Pacific

11.2.1.5.3.1. Market Estimation, 2013 – 2019

11.2.1.5.3.2. Market Forecast, 2020 – 2028

11.2.1.5.4. Middle East and Africa

11.2.1.5.4.1. Market Estimation, 2013 – 2019

11.2.1.5.4.2. Market Forecast, 2020 – 2028

11.2.1.5.5. Latin America

11.2.1.5.5.1. Market Estimation, 2013 – 2019

11.2.1.5.5.2. Market Forecast, 2020 – 2028

11.2.2. Obsessive Compulsive Disorder

11.2.2.1. Definition

11.2.2.2. Market Estimation and Penetration, 2013 – 2019

11.2.2.3. Market Forecast, 2020 – 2028

11.2.2.4. Compound Annual Growth Rate (CAGR)

11.2.2.5. Regional Bifurcation

11.2.2.5.1. North America

11.2.2.5.1.1. Market Estimation, 2013 – 2019

11.2.2.5.1.2. Market Forecast, 2020 – 2028

11.2.2.5.2. Europe

11.2.2.5.2.1. Market Estimation, 2013 – 2019

11.2.2.5.2.2. Market Forecast, 2020 – 2028

11.2.2.5.3. Asia Pacific

11.2.2.5.3.1. Market Estimation, 2013 – 2019

11.2.2.5.3.2. Market Forecast, 2020 – 2028

11.2.2.5.4. Middle East and Africa

11.2.2.5.4.1. Market Estimation, 2013 – 2019

11.2.2.5.4.2. Market Forecast, 2020 – 2028

11.2.2.5.5. Latin America

11.2.2.5.5.1. Market Estimation, 2013 – 2019

11.2.2.5.5.2. Market Forecast, 2020 – 2028

11.2.3. Generalized Anxiety

11.2.3.1. Definition

11.2.3.2. Market Estimation and Penetration, 2013 – 2019

11.2.3.3. Market Forecast, 2020 – 2028

11.2.3.4. Compound Annual Growth Rate (CAGR)

11.2.3.5. Regional Bifurcation

11.2.3.5.1. North America

11.2.3.5.1.1. Market Estimation, 2013 – 2019

11.2.3.5.1.2. Market Forecast, 2020 – 2028

11.2.3.5.2. Europe

11.2.3.5.2.1. Market Estimation, 2013 – 2019

11.2.3.5.2.2. Market Forecast, 2020 – 2028

11.2.3.5.3. Asia Pacific

11.2.3.5.3.1. Market Estimation, 2013 – 2019

11.2.3.5.3.2. Market Forecast, 2020 – 2028

11.2.3.5.4. Middle East and Africa

11.2.3.5.4.1. Market Estimation, 2013 – 2019

11.2.3.5.4.2. Market Forecast, 2020 – 2028

11.2.3.5.5. Latin America

11.2.3.5.5.1. Market Estimation, 2013 – 2019

11.2.3.5.5.2. Market Forecast, 2020 – 2028

11.2.4. Posttraumatic Stress (PTSD)

11.2.4.1. Definition

11.2.4.2. Market Estimation and Penetration, 2013 – 2019

11.2.4.3. Market Forecast, 2020 – 2028

11.2.4.4. Compound Annual Growth Rate (CAGR)

11.2.4.5. Regional Bifurcation

11.2.4.5.1. North America

11.2.4.5.1.1. Market Estimation, 2013 – 2019

11.2.4.5.1.2. Market Forecast, 2020 – 2028

11.2.4.5.2. Europe

11.2.4.5.2.1. Market Estimation, 2013 – 2019

11.2.4.5.2.2. Market Forecast, 2020 – 2028

11.2.4.5.3. Asia Pacific

11.2.4.5.3.1. Market Estimation, 2013 – 2019

11.2.4.5.3.2. Market Forecast, 2020 – 2028

11.2.4.5.4. Middle East and Africa

11.2.4.5.4.1. Market Estimation, 2013 – 2019

11.2.4.5.4.2. Market Forecast, 2020 – 2028

11.2.4.5.5. Latin America

11.2.4.5.5.1. Market Estimation, 2013 – 2019

11.2.4.5.5.2. Market Forecast, 2020 – 2028

11.2.5. Social Anxiety

11.2.5.1. Definition

11.2.5.2. Market Estimation and Penetration, 2013 – 2019

11.2.5.3. Market Forecast, 2020 – 2028

11.2.5.4. Compound Annual Growth Rate (CAGR)

11.2.5.5. Regional Bifurcation

11.2.5.5.1. North America

11.2.5.5.1.1. Market Estimation, 2013 – 2019

11.2.5.5.1.2. Market Forecast, 2020 – 2028

11.2.5.5.2. Europe

11.2.5.5.2.1. Market Estimation, 2013 – 2019

11.2.5.5.2.2. Market Forecast, 2020 – 2028

11.2.5.5.3. Asia Pacific

11.2.5.5.3.1. Market Estimation, 2013 – 2019

11.2.5.5.3.2. Market Forecast, 2020 – 2028

11.2.5.5.4. Middle East and Africa

11.2.5.5.4.1. Market Estimation, 2013 – 2019

11.2.5.5.4.2. Market Forecast, 2020 – 2028

11.2.5.5.5. Latin America

11.2.5.5.5.1. Market Estimation, 2013 – 2019

11.2.5.5.5.2. Market Forecast, 2020 – 2028

11.2.6. Agitation and Stress

11.2.6.1. Definition

11.2.6.2. Market Estimation and Penetration, 2013 – 2019

11.2.6.3. Market Forecast, 2020 – 2028

11.2.6.4. Compound Annual Growth Rate (CAGR)

11.2.6.5. Regional Bifurcation

11.2.6.5.1. North America

11.2.6.5.1.1. Market Estimation, 2013 – 2019

11.2.6.5.1.2. Market Forecast, 2020 – 2028

11.2.6.5.2. Europe

11.2.6.5.2.1. Market Estimation, 2013 – 2019

11.2.6.5.2.2. Market Forecast, 2020 – 2028

11.2.6.5.3. Asia Pacific

11.2.6.5.3.1. Market Estimation, 2013 – 2019

11.2.6.5.3.2. Market Forecast, 2020 – 2028

11.2.6.5.4. Middle East and Africa

11.2.6.5.4.1. Market Estimation, 2013 – 2019

11.2.6.5.4.2. Market Forecast, 2020 – 2028

11.2.6.5.5. Latin America

11.2.6.5.5.1. Market Estimation, 2013 – 2019

11.2.6.5.5.2. Market Forecast, 2020 – 2028

11.2.7. Bipolar Disorder

11.2.7.1. Definition

11.2.7.2. Market Estimation and Penetration, 2013 – 2019

11.2.7.3. Market Forecast, 2020 – 2028

11.2.7.4. Compound Annual Growth Rate (CAGR)

11.2.7.5. Regional Bifurcation

11.2.7.5.1. North America

11.2.7.5.1.1. Market Estimation, 2013 – 2019

11.2.7.5.1.2. Market Forecast, 2020 – 2028

11.2.7.5.2. Europe

11.2.7.5.2.1. Market Estimation, 2013 – 2019

11.2.7.5.2.2. Market Forecast, 2020 – 2028

11.2.7.5.3. Asia Pacific

11.2.7.5.3.1. Market Estimation, 2013 – 2019

11.2.7.5.3.2. Market Forecast, 2020 – 2028

11.2.7.5.4. Middle East and Africa

11.2.7.5.4.1. Market Estimation, 2013 – 2019

11.2.7.5.4.2. Market Forecast, 2020 – 2028

11.2.7.5.5. Latin America

11.2.7.5.5.1. Market Estimation, 2013 – 2019

11.2.7.5.5.2. Market Forecast, 2020 – 2028

11.2.8. Others

11.2.8.1. Definition

11.2.8.2. Market Estimation and Penetration, 2013 – 2019

11.2.8.3. Market Forecast, 2020 – 2028

11.2.8.4. Compound Annual Growth Rate (CAGR)

11.2.8.5. Regional Bifurcation

11.2.8.5.1. North America

11.2.8.5.1.1. Market Estimation, 2013 – 2019

11.2.8.5.1.2. Market Forecast, 2020 – 2028

11.2.8.5.2. Europe

11.2.8.5.2.1. Market Estimation, 2013 – 2019

11.2.8.5.2.2. Market Forecast, 2020 – 2028

11.2.8.5.3. Asia Pacific

11.2.8.5.3.1. Market Estimation, 2013 – 2019

11.2.8.5.3.2. Market Forecast, 2020 – 2028

11.2.8.5.4. Middle East and Africa

11.2.8.5.4.1. Market Estimation, 2013 – 2019

11.2.8.5.4.2. Market Forecast, 2020 – 2028

11.2.8.5.5. Latin America

11.2.8.5.5.1. Market Estimation, 2013 – 2019

11.2.8.5.5.2. Market Forecast, 2020 – 2028

11.3. Key Segment for Channeling Investments

11.3.1. By Disorder Type

12. North America Antidepressant Drugs Market Analysis and Forecasts, 2020 - 2028

12.1. Overview

12.1.1. North America Antidepressant Drugs Market Revenue (US$ Mn)

12.2. North America Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By Type

12.2.1. Serotonin and Noradrenaline Reuptake Inhibitors (SNRIs)

12.2.2. Selective Serotonin Reuptake Inhibitors (SSRIs)

12.2.3. Tricyclic Antidepressants (TCAs)

12.2.4. Monoamine Oxidase Inhibitors (MAOIs)

12.2.5. Noradrenaline and Specific Serotoninergic Antidepressants (NaSSAs)

12.3. North America Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By Mode of Administration

12.3.1. Tablets and Capsules

12.3.2. Liquids

12.3.3. Injections

12.3.4. Inhalation

12.3.5. Others

12.4. North America Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By End-Users

12.4.1. Hospitals and Clinics

12.4.2. Pharmacies

12.4.3. Urgent Care Centers

12.4.4. Research Institutes

12.4.5. Others

12.5. North America Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By Disorder Type

12.5.1. Major and Minor Depression

12.5.2. Obsessive Compulsive Disorder

12.5.3. Generalized Anxiety

12.5.4. Posttraumatic Stress (PTSD)

12.5.5. Social Anxiety

12.5.6. Agitation and Stress

12.5.7. Bipolar Disorder

12.5.8. Others

12.6. North America Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By Country

12.6.1. U.S

12.6.1.1. U.S Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By Type

12.6.1.1.1. Serotonin and Noradrenaline Reuptake Inhibitors (SNRIs)

12.6.1.1.2. Selective Serotonin Reuptake Inhibitors (SSRIs)

12.6.1.1.3. Tricyclic Antidepressants (TCAs)

12.6.1.1.4. Monoamine Oxidase Inhibitors (MAOIs)

12.6.1.1.5. Noradrenaline and Specific Serotoninergic Antidepressants (NaSSAs)

12.6.1.2. U.S Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By Mode of Administration

12.6.1.2.1. Tablets and Capsules

12.6.1.2.2. Liquids

12.6.1.2.3. Injections

12.6.1.2.4. Inhalation

12.6.1.2.5. Others

12.6.1.3. U.S Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By End-Users

12.6.1.3.1. Hospitals and Clinics

12.6.1.3.2. Pharmacies

12.6.1.3.3. Urgent Care Centers

12.6.1.3.4. Research Institutes

12.6.1.3.5. Others

12.6.1.4. U.S Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By Disorder Type

12.6.1.4.1. Major and Minor Depression

12.6.1.4.2. Obsessive Compulsive Disorder

12.6.1.4.3. Generalized Anxiety

12.6.1.4.4. Posttraumatic Stress (PTSD)

12.6.1.4.5. Social Anxiety

12.6.1.4.6. Agitation and Stress

12.6.1.4.7. Bipolar Disorder

12.6.1.4.8. Others

12.6.2. Canada

12.6.2.1. Canada Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By Type

12.6.2.1.1. Serotonin and Noradrenaline Reuptake Inhibitors (SNRIs)

12.6.2.1.2. Selective Serotonin Reuptake Inhibitors (SSRIs)

12.6.2.1.3. Tricyclic Antidepressants (TCAs)

12.6.2.1.4. Monoamine Oxidase Inhibitors (MAOIs)

12.6.2.1.5. Noradrenaline and Specific Serotoninergic Antidepressants (NaSSAs)

12.6.2.2. Canada Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By Mode of Administration

12.6.2.2.1. Tablets and Capsules

12.6.2.2.2. Liquids

12.6.2.2.3. Injections

12.6.2.2.4. Inhalation

12.6.2.2.5. Others

12.6.2.3. Canada Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By End-Users

12.6.2.3.1. Hospitals and Clinics

12.6.2.3.2. Pharmacies

12.6.2.3.3. Urgent Care Centers

12.6.2.3.4. Research Institutes

12.6.2.3.5. Others

12.6.2.4. Canada Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By Disorder Type

12.6.2.4.1. Major and Minor Depression

12.6.2.4.2. Obsessive Compulsive Disorder

12.6.2.4.3. Generalized Anxiety

12.6.2.4.4. Posttraumatic Stress (PTSD)

12.6.2.4.5. Social Anxiety

12.6.2.4.6. Agitation and Stress

12.6.2.4.7. Bipolar Disorder

12.6.2.4.8. Others

12.6.3. Mexico

12.6.3.1. Mexico Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By Type

12.6.3.1.1. Serotonin and Noradrenaline Reuptake Inhibitors (SNRIs)

12.6.3.1.2. Selective Serotonin Reuptake Inhibitors (SSRIs)

12.6.3.1.3. Tricyclic Antidepressants (TCAs)

12.6.3.1.4. Monoamine Oxidase Inhibitors (MAOIs)

12.6.3.1.5. Noradrenaline and Specific Serotoninergic Antidepressants (NaSSAs)

12.6.3.2. Mexico Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By Mode of Administration

12.6.3.2.1. Tablets and Capsules

12.6.3.2.2. Liquids

12.6.3.2.3. Injections

12.6.3.2.4. Inhalation

12.6.3.2.5. Others

12.6.3.3. Mexico Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By End-Users

12.6.3.3.1. Hospitals and Clinics

12.6.3.3.2. Pharmacies

12.6.3.3.3. Urgent Care Centers

12.6.3.3.4. Research Institutes

12.6.3.3.5. Others

12.6.3.4. Mexico Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By Disorder Type

12.6.3.4.1. Major and Minor Depression

12.6.3.4.2. Obsessive Compulsive Disorder

12.6.3.4.3. Generalized Anxiety

12.6.3.4.4. Posttraumatic Stress (PTSD)

12.6.3.4.5. Social Anxiety

12.6.3.4.6. Agitation and Stress

12.6.3.4.7. Bipolar Disorder

12.6.3.4.8. Others

12.6.4. Rest of North America

12.6.4.1. Rest of North America Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By Type

12.6.4.1.1. Serotonin and Noradrenaline Reuptake Inhibitors (SNRIs)

12.6.4.1.2. Selective Serotonin Reuptake Inhibitors (SSRIs)

12.6.4.1.3. Tricyclic Antidepressants (TCAs)

12.6.4.1.4. Monoamine Oxidase Inhibitors (MAOIs)

12.6.4.1.5. Noradrenaline and Specific Serotoninergic Antidepressants (NaSSAs)

12.6.4.2. Rest of North America Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By Mode of Administration

12.6.4.2.1. Tablets and Capsules

12.6.4.2.2. Liquids

12.6.4.2.3. Injections

12.6.4.2.4. Inhalation

12.6.4.2.5. Others

12.6.4.3. Rest of North America Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By End-Users

12.6.4.3.1. Hospitals and Clinics

12.6.4.3.2. Pharmacies

12.6.4.3.3. Urgent Care Centers

12.6.4.3.4. Research Institutes

12.6.4.3.5. Others

12.6.4.4. Rest of North America Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By Disorder Type

12.6.4.4.1. Major and Minor Depression

12.6.4.4.2. Obsessive Compulsive Disorder

12.6.4.4.3. Generalized Anxiety

12.6.4.4.4. Posttraumatic Stress (PTSD)

12.6.4.4.5. Social Anxiety

12.6.4.4.6. Agitation and Stress

12.6.4.4.7. Bipolar Disorder

12.6.4.4.8. Others

12.7. Key Segment for Channeling Investments

12.7.1. By Country

12.7.2. By Type

12.7.3. By Mode of Administration

12.7.4. By End-Users

12.7.5. By Disorder Type

13. Europe Antidepressant Drugs Market Analysis and Forecasts, 2020 - 2028

13.1. Overview

13.1.1. Europe Antidepressant Drugs Market Revenue (US$ Mn)

13.2. Europe Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By Type

13.2.1. Serotonin and Noradrenaline Reuptake Inhibitors (SNRIs)

13.2.2. Selective Serotonin Reuptake Inhibitors (SSRIs)

13.2.3. Tricyclic Antidepressants (TCAs)

13.2.4. Monoamine Oxidase Inhibitors (MAOIs)

13.2.5. Noradrenaline and Specific Serotoninergic Antidepressants (NaSSAs)

13.3. Europe Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By Mode of Administration

13.3.1. Tablets and Capsules

13.3.2. Liquids

13.3.3. Injections

13.3.4. Inhalation

13.3.5. Others

13.4. Europe Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By End-Users

13.4.1. Hospitals and Clinics

13.4.2. Pharmacies

13.4.3. Urgent Care Centers

13.4.4. Research Institutes

13.4.5. Others

13.5. Europe Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By Disorder Type

13.5.1. Major and Minor Depression

13.5.2. Obsessive Compulsive Disorder

13.5.3. Generalized Anxiety

13.5.4. Posttraumatic Stress (PTSD)

13.5.5. Social Anxiety

13.5.6. Agitation and Stress

13.5.7. Bipolar Disorder

13.5.8. Others

13.6. Europe Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By Country

13.6.1. France

13.6.1.1. France Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By Type

13.6.1.1.1. Serotonin and Noradrenaline Reuptake Inhibitors (SNRIs)

13.6.1.1.2. Selective Serotonin Reuptake Inhibitors (SSRIs)

13.6.1.1.3. Tricyclic Antidepressants (TCAs)

13.6.1.1.4. Monoamine Oxidase Inhibitors (MAOIs)

13.6.1.1.5. Noradrenaline and Specific Serotoninergic Antidepressants (NaSSAs)

13.6.1.2. France Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By Mode of Administration

13.6.1.2.1. Tablets and Capsules

13.6.1.2.2. Liquids

13.6.1.2.3. Injections

13.6.1.2.4. Inhalation

13.6.1.2.5. Others

13.6.1.3. France Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By End-Users

13.6.1.3.1. Hospitals and Clinics

13.6.1.3.2. Pharmacies

13.6.1.3.3. Urgent Care Centers

13.6.1.3.4. Research Institutes

13.6.1.3.5. Others

13.6.1.4. France Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By Disorder Type

13.6.1.4.1. Major and Minor Depression

13.6.1.4.2. Obsessive Compulsive Disorder

13.6.1.4.3. Generalized Anxiety

13.6.1.4.4. Posttraumatic Stress (PTSD)

13.6.1.4.5. Social Anxiety

13.6.1.4.6. Agitation and Stress

13.6.1.4.7. Bipolar Disorder

13.6.1.4.8. Others

13.6.2. The UK

13.6.2.1. The UK Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By Type

13.6.2.1.1. Serotonin and Noradrenaline Reuptake Inhibitors (SNRIs)

13.6.2.1.2. Selective Serotonin Reuptake Inhibitors (SSRIs)

13.6.2.1.3. Tricyclic Antidepressants (TCAs)

13.6.2.1.4. Monoamine Oxidase Inhibitors (MAOIs)

13.6.2.1.5. Noradrenaline and Specific Serotoninergic Antidepressants (NaSSAs)

13.6.2.2. The UK Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By Mode of Administration

13.6.2.2.1. Tablets and Capsules

13.6.2.2.2. Liquids

13.6.2.2.3. Injections

13.6.2.2.4. Inhalation

13.6.2.2.5. Others

13.6.2.3. The UK Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By End-Users

13.6.2.3.1. Hospitals and Clinics

13.6.2.3.2. Pharmacies

13.6.2.3.3. Urgent Care Centers

13.6.2.3.4. Research Institutes

13.6.2.3.5. Others

13.6.2.4. The UK Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By Disorder Type

13.6.2.4.1. Major and Minor Depression

13.6.2.4.2. Obsessive Compulsive Disorder

13.6.2.4.3. Generalized Anxiety

13.6.2.4.4. Posttraumatic Stress (PTSD)

13.6.2.4.5. Social Anxiety

13.6.2.4.6. Agitation and Stress

13.6.2.4.7. Bipolar Disorder

13.6.2.4.8. Others

13.6.3. Spain

13.6.3.1. Spain Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By Type

13.6.3.1.1. Serotonin and Noradrenaline Reuptake Inhibitors (SNRIs)

13.6.3.1.2. Selective Serotonin Reuptake Inhibitors (SSRIs)

13.6.3.1.3. Tricyclic Antidepressants (TCAs)

13.6.3.1.4. Monoamine Oxidase Inhibitors (MAOIs)

13.6.3.1.5. Noradrenaline and Specific Serotoninergic Antidepressants (NaSSAs)

13.6.3.2. Spain Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By Mode of Administration

13.6.3.2.1. Tablets and Capsules

13.6.3.2.2. Liquids

13.6.3.2.3. Injections

13.6.3.2.4. Inhalation

13.6.3.2.5. Others

13.6.3.3. Spain Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By End-Users

13.6.3.3.1. Hospitals and Clinics

13.6.3.3.2. Pharmacies

13.6.3.3.3. Urgent Care Centers

13.6.3.3.4. Research Institutes

13.6.3.3.5. Others

13.6.3.4. Spain Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By Disorder Type

13.6.3.4.1. Major and Minor Depression

13.6.3.4.2. Obsessive Compulsive Disorder

13.6.3.4.3. Generalized Anxiety

13.6.3.4.4. Posttraumatic Stress (PTSD)

13.6.3.4.5. Social Anxiety

13.6.3.4.6. Agitation and Stress

13.6.3.4.7. Bipolar Disorder

13.6.3.4.8. Others

13.6.4. Germany

13.6.4.1. Germany Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By Type

13.6.4.1.1. Serotonin and Noradrenaline Reuptake Inhibitors (SNRIs)

13.6.4.1.2. Selective Serotonin Reuptake Inhibitors (SSRIs)

13.6.4.1.3. Tricyclic Antidepressants (TCAs)

13.6.4.1.4. Monoamine Oxidase Inhibitors (MAOIs)

13.6.4.1.5. Noradrenaline and Specific Serotoninergic Antidepressants (NaSSAs)

13.6.4.2. Germany Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By Mode of Administration

13.6.4.2.1. Tablets and Capsules

13.6.4.2.2. Liquids

13.6.4.2.3. Injections

13.6.4.2.4. Inhalation

13.6.4.2.5. Others

13.6.4.3. Germany Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By End-Users

13.6.4.3.1. Hospitals and Clinics

13.6.4.3.2. Pharmacies

13.6.4.3.3. Urgent Care Centers

13.6.4.3.4. Research Institutes

13.6.4.3.5. Others

13.6.4.4. Germany Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By Disorder Type

13.6.4.4.1. Major and Minor Depression

13.6.4.4.2. Obsessive Compulsive Disorder

13.6.4.4.3. Generalized Anxiety

13.6.4.4.4. Posttraumatic Stress (PTSD)

13.6.4.4.5. Social Anxiety

13.6.4.4.6. Agitation and Stress

13.6.4.4.7. Bipolar Disorder

13.6.4.4.8. Others

13.6.5. Italy

13.6.5.1. Italy Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By Type

13.6.5.1.1. Serotonin and Noradrenaline Reuptake Inhibitors (SNRIs)

13.6.5.1.2. Selective Serotonin Reuptake Inhibitors (SSRIs)

13.6.5.1.3. Tricyclic Antidepressants (TCAs)

13.6.5.1.4. Monoamine Oxidase Inhibitors (MAOIs)

13.6.5.1.5. Noradrenaline and Specific Serotoninergic Antidepressants (NaSSAs)

13.6.5.2. Italy Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By Mode of Administration

13.6.5.2.1. Tablets and Capsules

13.6.5.2.2. Liquids

13.6.5.2.3. Injections

13.6.5.2.4. Inhalation

13.6.5.2.5. Others

13.6.5.3. Italy Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By End-Users

13.6.5.3.1. Hospitals and Clinics

13.6.5.3.2. Pharmacies

13.6.5.3.3. Urgent Care Centers

13.6.5.3.4. Research Institutes

13.6.5.3.5. Others

13.6.5.4. Italy Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By Disorder Type

13.6.5.4.1. Major and Minor Depression

13.6.5.4.2. Obsessive Compulsive Disorder

13.6.5.4.3. Generalized Anxiety

13.6.5.4.4. Posttraumatic Stress (PTSD)

13.6.5.4.5. Social Anxiety

13.6.5.4.6. Agitation and Stress

13.6.5.4.7. Bipolar Disorder

13.6.5.4.8. Others

13.6.6. Nordic Countries

13.6.6.1. Nordic Countries Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By Type

13.6.6.1.1. Serotonin and Noradrenaline Reuptake Inhibitors (SNRIs)

13.6.6.1.2. Selective Serotonin Reuptake Inhibitors (SSRIs)

13.6.6.1.3. Tricyclic Antidepressants (TCAs)

13.6.6.1.4. Monoamine Oxidase Inhibitors (MAOIs)

13.6.6.1.5. Noradrenaline and Specific Serotoninergic Antidepressants (NaSSAs)

13.6.6.2. Nordic Countries Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By Mode of Administration

13.6.6.2.1. Tablets and Capsules

13.6.6.2.2. Liquids

13.6.6.2.3. Injections

13.6.6.2.4. Inhalation

13.6.6.2.5. Others

13.6.6.3. Nordic Countries Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By End-Users

13.6.6.3.1. Hospitals and Clinics

13.6.6.3.2. Pharmacies

13.6.6.3.3. Urgent Care Centers

13.6.6.3.4. Research Institutes

13.6.6.3.5. Others

13.6.6.4. Nordic Countries Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By Disorder Type

13.6.6.4.1. Major and Minor Depression

13.6.6.4.2. Obsessive Compulsive Disorder

13.6.6.4.3. Generalized Anxiety

13.6.6.4.4. Posttraumatic Stress (PTSD)

13.6.6.4.5. Social Anxiety

13.6.6.4.6. Agitation and Stress

13.6.6.4.7. Bipolar Disorder

13.6.6.4.8. Others

13.6.6.5. Nordic Countries Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By Country

13.6.6.5.1. Denmark

13.6.6.5.2. Finland

13.6.6.5.3. Iceland

13.6.6.5.4. Sweden

13.6.6.5.5. Norway

13.6.7. Benelux Union

13.6.7.1. Benelux Union Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By Type

13.6.7.1.1. Serotonin and Noradrenaline Reuptake Inhibitors (SNRIs)

13.6.7.1.2. Selective Serotonin Reuptake Inhibitors (SSRIs)

13.6.7.1.3. Tricyclic Antidepressants (TCAs)

13.6.7.1.4. Monoamine Oxidase Inhibitors (MAOIs)

13.6.7.1.5. Noradrenaline and Specific Serotoninergic Antidepressants (NaSSAs)

13.6.7.2. Benelux Union Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By Mode of Administration

13.6.7.2.1. Tablets and Capsules

13.6.7.2.2. Liquids

13.6.7.2.3. Injections

13.6.7.2.4. Inhalation

13.6.7.2.5. Others

13.6.7.3. Benelux Union Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By End-Users

13.6.7.3.1. Hospitals and Clinics

13.6.7.3.2. Pharmacies

13.6.7.3.3. Urgent Care Centers

13.6.7.3.4. Research Institutes

13.6.7.3.5. Others

13.6.7.4. Benelux Union Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By Disorder Type

13.6.7.4.1. Major and Minor Depression

13.6.7.4.2. Obsessive Compulsive Disorder

13.6.7.4.3. Generalized Anxiety

13.6.7.4.4. Posttraumatic Stress (PTSD)

13.6.7.4.5. Social Anxiety

13.6.7.4.6. Agitation and Stress

13.6.7.4.7. Bipolar Disorder

13.6.7.4.8. Others

13.6.7.5. Benelux Union Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By Country

13.6.7.5.1. Belgium

13.6.7.5.2. The Netherlands

13.6.7.5.3. Luxembourg

13.6.8. Rest of Europe

13.6.8.1. Rest of Europe Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By Type

13.6.8.1.1. Serotonin and Noradrenaline Reuptake Inhibitors (SNRIs)

13.6.8.1.2. Selective Serotonin Reuptake Inhibitors (SSRIs)

13.6.8.1.3. Tricyclic Antidepressants (TCAs)

13.6.8.1.4. Monoamine Oxidase Inhibitors (MAOIs)

13.6.8.1.5. Noradrenaline and Specific Serotoninergic Antidepressants (NaSSAs)

13.6.8.2. Rest of Europe Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By Mode of Administration

13.6.8.2.1. Tablets and Capsules

13.6.8.2.2. Liquids

13.6.8.2.3. Injections

13.6.8.2.4. Inhalation

13.6.8.2.5. Others

13.6.8.3. Rest of Europe Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By End-Users

13.6.8.3.1. Hospitals and Clinics

13.6.8.3.2. Pharmacies

13.6.8.3.3. Urgent Care Centers

13.6.8.3.4. Research Institutes

13.6.8.3.5. Others

13.6.8.4. Rest of Europe Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By Disorder Type

13.6.8.4.1. Major and Minor Depression

13.6.8.4.2. Obsessive Compulsive Disorder

13.6.8.4.3. Generalized Anxiety

13.6.8.4.4. Posttraumatic Stress (PTSD)

13.6.8.4.5. Social Anxiety

13.6.8.4.6. Agitation and Stress

13.6.8.4.7. Bipolar Disorder

13.6.8.4.8. Others

13.7. Key Segment for Channeling Investments

13.7.1. By Country

13.7.2. By Type

13.7.3. By Mode of Administration

13.7.4. By End-Users

13.7.5. By Disorder Type

14. Asia Pacific Antidepressant Drugs Market Analysis and Forecasts, 2020 - 2028

14.1. Overview

14.1.1. Asia Pacific Antidepressant Drugs Market Revenue (US$ Mn)

14.2. Asia Pacific Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By Type

14.2.1. Serotonin and Noradrenaline Reuptake Inhibitors (SNRIs)

14.2.2. Selective Serotonin Reuptake Inhibitors (SSRIs)

14.2.3. Tricyclic Antidepressants (TCAs)

14.2.4. Monoamine Oxidase Inhibitors (MAOIs)

14.2.5. Noradrenaline and Specific Serotoninergic Antidepressants (NaSSAs)

14.3. Asia Pacific Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By Mode of Administration

14.3.1. Tablets and Capsules

14.3.2. Liquids

14.3.3. Injections

14.3.4. Inhalation

14.3.5. Others

14.4. Asia Pacific Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By End-Users

14.4.1. Hospitals and Clinics

14.4.2. Pharmacies

14.4.3. Urgent Care Centers

14.4.4. Research Institutes

14.4.5. Others

14.5. Asia Pacific Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By Disorder Type

14.5.1. Major and Minor Depression

14.5.2. Obsessive Compulsive Disorder

14.5.3. Generalized Anxiety

14.5.4. Posttraumatic Stress (PTSD)

14.5.5. Social Anxiety

14.5.6. Agitation and Stress

14.5.7. Bipolar Disorder

14.5.8. Others

14.6. Asia Pacific Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By Country

14.6.1. China

14.6.1.1. China Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By Type

14.6.1.1.1. Serotonin and Noradrenaline Reuptake Inhibitors (SNRIs)

14.6.1.1.2. Selective Serotonin Reuptake Inhibitors (SSRIs)

14.6.1.1.3. Tricyclic Antidepressants (TCAs)

14.6.1.1.4. Monoamine Oxidase Inhibitors (MAOIs)

14.6.1.1.5. Noradrenaline and Specific Serotoninergic Antidepressants (NaSSAs)

14.6.1.2. China Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By Mode of Administration

14.6.1.2.1. Tablets and Capsules

14.6.1.2.2. Liquids

14.6.1.2.3. Injections

14.6.1.2.4. Inhalation

14.6.1.2.5. Others

14.6.1.3. China Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By End-Users

14.6.1.3.1. Hospitals and Clinics

14.6.1.3.2. Pharmacies

14.6.1.3.3. Urgent Care Centers

14.6.1.3.4. Research Institutes

14.6.1.3.5. Others

14.6.1.4. China Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By Disorder Type

14.6.1.4.1. Major and Minor Depression

14.6.1.4.2. Obsessive Compulsive Disorder

14.6.1.4.3. Generalized Anxiety

14.6.1.4.4. Posttraumatic Stress (PTSD)

14.6.1.4.5. Social Anxiety

14.6.1.4.6. Agitation and Stress

14.6.1.4.7. Bipolar Disorder

14.6.1.4.8. Others

14.6.2. Japan

14.6.2.1. Japan Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By Type

14.6.2.1.1. Serotonin and Noradrenaline Reuptake Inhibitors (SNRIs)

14.6.2.1.2. Selective Serotonin Reuptake Inhibitors (SSRIs)

14.6.2.1.3. Tricyclic Antidepressants (TCAs)

14.6.2.1.4. Monoamine Oxidase Inhibitors (MAOIs)

14.6.2.1.5. Noradrenaline and Specific Serotoninergic Antidepressants (NaSSAs)

14.6.2.2. Japan Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By Mode of Administration

14.6.2.2.1. Tablets and Capsules

14.6.2.2.2. Liquids

14.6.2.2.3. Injections

14.6.2.2.4. Inhalation

14.6.2.2.5. Others

14.6.2.3. Japan Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By End-Users

14.6.2.3.1. Hospitals and Clinics

14.6.2.3.2. Pharmacies

14.6.2.3.3. Urgent Care Centers

14.6.2.3.4. Research Institutes

14.6.2.3.5. Others

14.6.2.4. Japan Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By Disorder Type

14.6.2.4.1. Major and Minor Depression

14.6.2.4.2. Obsessive Compulsive Disorder

14.6.2.4.3. Generalized Anxiety

14.6.2.4.4. Posttraumatic Stress (PTSD)

14.6.2.4.5. Social Anxiety

14.6.2.4.6. Agitation and Stress

14.6.2.4.7. Bipolar Disorder

14.6.2.4.8. Others

14.6.3. India

14.6.3.1. India Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By Type

14.6.3.1.1. Serotonin and Noradrenaline Reuptake Inhibitors (SNRIs)

14.6.3.1.2. Selective Serotonin Reuptake Inhibitors (SSRIs)

14.6.3.1.3. Tricyclic Antidepressants (TCAs)

14.6.3.1.4. Monoamine Oxidase Inhibitors (MAOIs)

14.6.3.1.5. Noradrenaline and Specific Serotoninergic Antidepressants (NaSSAs)

14.6.3.2. India Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By Mode of Administration

14.6.3.2.1. Tablets and Capsules

14.6.3.2.2. Liquids

14.6.3.2.3. Injections

14.6.3.2.4. Inhalation

14.6.3.2.5. Others

14.6.3.3. India Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By End-Users

14.6.3.3.1. Hospitals and Clinics

14.6.3.3.2. Pharmacies

14.6.3.3.3. Urgent Care Centers

14.6.3.3.4. Research Institutes

14.6.3.3.5. Others

14.6.3.4. India Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By Disorder Type

14.6.3.4.1. Major and Minor Depression

14.6.3.4.2. Obsessive Compulsive Disorder

14.6.3.4.3. Generalized Anxiety

14.6.3.4.4. Posttraumatic Stress (PTSD)

14.6.3.4.5. Social Anxiety

14.6.3.4.6. Agitation and Stress

14.6.3.4.7. Bipolar Disorder

14.6.3.4.8. Others

14.6.4. New Zealand

14.6.4.1. New Zealand Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By Type

14.6.4.1.1. Serotonin and Noradrenaline Reuptake Inhibitors (SNRIs)

14.6.4.1.2. Selective Serotonin Reuptake Inhibitors (SSRIs)

14.6.4.1.3. Tricyclic Antidepressants (TCAs)

14.6.4.1.4. Monoamine Oxidase Inhibitors (MAOIs)

14.6.4.1.5. Noradrenaline and Specific Serotoninergic Antidepressants (NaSSAs)

14.6.4.2. New Zealand Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By Mode of Administration

14.6.4.2.1. Tablets and Capsules

14.6.4.2.2. Liquids

14.6.4.2.3. Injections

14.6.4.2.4. Inhalation

14.6.4.2.5. Others

14.6.4.3. New Zealand Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By End-Users

14.6.4.3.1. Hospitals and Clinics

14.6.4.3.2. Pharmacies

14.6.4.3.3. Urgent Care Centers

14.6.4.3.4. Research Institutes

14.6.4.3.5. Others

14.6.4.4. New Zealand Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By Disorder Type

14.6.4.4.1. Major and Minor Depression

14.6.4.4.2. Obsessive Compulsive Disorder

14.6.4.4.3. Generalized Anxiety

14.6.4.4.4. Posttraumatic Stress (PTSD)

14.6.4.4.5. Social Anxiety

14.6.4.4.6. Agitation and Stress

14.6.4.4.7. Bipolar Disorder

14.6.4.4.8. Others

14.6.5. Australia

14.6.5.1. Australia Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By Type

14.6.5.1.1. Serotonin and Noradrenaline Reuptake Inhibitors (SNRIs)

14.6.5.1.2. Selective Serotonin Reuptake Inhibitors (SSRIs)

14.6.5.1.3. Tricyclic Antidepressants (TCAs)

14.6.5.1.4. Monoamine Oxidase Inhibitors (MAOIs)

14.6.5.1.5. Noradrenaline and Specific Serotoninergic Antidepressants (NaSSAs)

14.6.5.2. Australia Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By Mode of Administration

14.6.5.2.1. Tablets and Capsules

14.6.5.2.2. Liquids

14.6.5.2.3. Injections

14.6.5.2.4. Inhalation

14.6.5.2.5. Others

14.6.5.3. Australia Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By End-Users

14.6.5.3.1. Hospitals and Clinics

14.6.5.3.2. Pharmacies

14.6.5.3.3. Urgent Care Centers

14.6.5.3.4. Research Institutes

14.6.5.3.5. Others

14.6.5.4. Australia Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By Disorder Type

14.6.5.4.1. Major and Minor Depression

14.6.5.4.2. Obsessive Compulsive Disorder

14.6.5.4.3. Generalized Anxiety

14.6.5.4.4. Posttraumatic Stress (PTSD)

14.6.5.4.5. Social Anxiety

14.6.5.4.6. Agitation and Stress

14.6.5.4.7. Bipolar Disorder

14.6.5.4.8. Others

14.6.6. South Korea

14.6.6.1. South Korea Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By Type

14.6.6.1.1. Serotonin and Noradrenaline Reuptake Inhibitors (SNRIs)

14.6.6.1.2. Selective Serotonin Reuptake Inhibitors (SSRIs)

14.6.6.1.3. Tricyclic Antidepressants (TCAs)

14.6.6.1.4. Monoamine Oxidase Inhibitors (MAOIs)

14.6.6.1.5. Noradrenaline and Specific Serotoninergic Antidepressants (NaSSAs)

14.6.6.2. South Korea Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By Mode of Administration

14.6.6.2.1. Tablets and Capsules

14.6.6.2.2. Liquids

14.6.6.2.3. Injections

14.6.6.2.4. Inhalation

14.6.6.2.5. Others

14.6.6.3. South Korea Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By End-Users

14.6.6.3.1. Hospitals and Clinics

14.6.6.3.2. Pharmacies

14.6.6.3.3. Urgent Care Centers

14.6.6.3.4. Research Institutes

14.6.6.3.5. Others

14.6.6.4. South Korea Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By Disorder Type

14.6.6.4.1. Major and Minor Depression

14.6.6.4.2. Obsessive Compulsive Disorder

14.6.6.4.3. Generalized Anxiety

14.6.6.4.4. Posttraumatic Stress (PTSD)

14.6.6.4.5. Social Anxiety

14.6.6.4.6. Agitation and Stress

14.6.6.4.7. Bipolar Disorder

14.6.6.4.8. Others

14.6.7. Southeast Asia

14.6.7.1. Southeast Asia Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By Type

14.6.7.1.1. Serotonin and Noradrenaline Reuptake Inhibitors (SNRIs)

14.6.7.1.2. Selective Serotonin Reuptake Inhibitors (SSRIs)

14.6.7.1.3. Tricyclic Antidepressants (TCAs)

14.6.7.1.4. Monoamine Oxidase Inhibitors (MAOIs)

14.6.7.1.5. Noradrenaline and Specific Serotoninergic Antidepressants (NaSSAs)

14.6.7.2. Southeast Asia Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By Mode of Administration

14.6.7.2.1. Tablets and Capsules

14.6.7.2.2. Liquids

14.6.7.2.3. Injections

14.6.7.2.4. Inhalation

14.6.7.2.5. Others

14.6.7.3. Southeast Asia Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By End-Users

14.6.7.3.1. Hospitals and Clinics

14.6.7.3.2. Pharmacies

14.6.7.3.3. Urgent Care Centers

14.6.7.3.4. Research Institutes

14.6.7.3.5. Others

14.6.7.4. Southeast Asia Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By Disorder Type

14.6.7.4.1. Major and Minor Depression

14.6.7.4.2. Obsessive Compulsive Disorder

14.6.7.4.3. Generalized Anxiety

14.6.7.4.4. Posttraumatic Stress (PTSD)

14.6.7.4.5. Social Anxiety

14.6.7.4.6. Agitation and Stress

14.6.7.4.7. Bipolar Disorder

14.6.7.4.8. Others

14.6.7.5. Southeast Asia Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By Country

14.6.7.5.1. Indonesia

14.6.7.5.2. Thailand

14.6.7.5.3. Malaysia

14.6.7.5.4. Singapore

14.6.7.5.5. Rest of Southeast Asia

14.6.8. Rest of Asia Pacific

14.6.8.1. Rest of Asia Pacific Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By Type

14.6.8.1.1. Serotonin and Noradrenaline Reuptake Inhibitors (SNRIs)

14.6.8.1.2. Selective Serotonin Reuptake Inhibitors (SSRIs)

14.6.8.1.3. Tricyclic Antidepressants (TCAs)

14.6.8.1.4. Monoamine Oxidase Inhibitors (MAOIs)

14.6.8.1.5. Noradrenaline and Specific Serotoninergic Antidepressants (NaSSAs)

14.6.8.2. Rest of Asia Pacific Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By Mode of Administration

14.6.8.2.1. Tablets and Capsules

14.6.8.2.2. Liquids

14.6.8.2.3. Injections

14.6.8.2.4. Inhalation

14.6.8.2.5. Others

14.6.8.3. Rest of Asia Pacific Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By End-Users

14.6.8.3.1. Hospitals and Clinics

14.6.8.3.2. Pharmacies

14.6.8.3.3. Urgent Care Centers

14.6.8.3.4. Research Institutes

14.6.8.3.5. Others

14.6.8.4. Rest of Asia Pacific Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By Disorder Type

14.6.8.4.1. Major and Minor Depression

14.6.8.4.2. Obsessive Compulsive Disorder

14.6.8.4.3. Generalized Anxiety

14.6.8.4.4. Posttraumatic Stress (PTSD)

14.6.8.4.5. Social Anxiety

14.6.8.4.6. Agitation and Stress

14.6.8.4.7. Bipolar Disorder

14.6.8.4.8. Others

14.7. Key Segment for Channeling Investments

14.7.1. By Country

14.7.2. By Type

14.7.3. By Mode of Administration

14.7.4. By End-Users

14.7.5. By Disorder Type

15. Middle East and Africa Antidepressant Drugs Market Analysis and Forecasts, 2020 - 2028

15.1. Overview

15.1.1. Middle East and Africa Antidepressant Drugs Market Revenue (US$ Mn)

15.2. Middle East and Africa Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By Type

15.2.1. Serotonin and Noradrenaline Reuptake Inhibitors (SNRIs)

15.2.2. Selective Serotonin Reuptake Inhibitors (SSRIs)

15.2.3. Tricyclic Antidepressants (TCAs)

15.2.4. Monoamine Oxidase Inhibitors (MAOIs)

15.2.5. Noradrenaline and Specific Serotoninergic Antidepressants (NaSSAs)

15.3. Middle East and Africa Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By Mode of Administration

15.3.1. Tablets and Capsules

15.3.2. Liquids

15.3.3. Injections

15.3.4. Inhalation

15.3.5. Others

15.4. Middle East and Africa Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By End-Users

15.4.1. Hospitals and Clinics

15.4.2. Pharmacies

15.4.3. Urgent Care Centers

15.4.4. Research Institutes

15.4.5. Others

15.5. Middle East and Africa Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By Disorder Type

15.5.1. Major and Minor Depression

15.5.2. Obsessive Compulsive Disorder

15.5.3. Generalized Anxiety

15.5.4. Posttraumatic Stress (PTSD)

15.5.5. Social Anxiety

15.5.6. Agitation and Stress

15.5.7. Bipolar Disorder

15.5.8. Others

15.6. Middle East and Africa Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By Country

15.6.1. Saudi Arabia

15.6.1.1. Saudi Arabia Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By Type

15.6.1.1.1. Serotonin and Noradrenaline Reuptake Inhibitors (SNRIs)

15.6.1.1.2. Selective Serotonin Reuptake Inhibitors (SSRIs)

15.6.1.1.3. Tricyclic Antidepressants (TCAs)

15.6.1.1.4. Monoamine Oxidase Inhibitors (MAOIs)

15.6.1.1.5. Noradrenaline and Specific Serotoninergic Antidepressants (NaSSAs)

15.6.1.2. Saudi Arabia Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By Mode of Administration

15.6.1.2.1. Tablets and Capsules

15.6.1.2.2. Liquids

15.6.1.2.3. Injections

15.6.1.2.4. Inhalation

15.6.1.2.5. Others

15.6.1.3. Saudi Arabia Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By End-Users

15.6.1.3.1. Hospitals and Clinics

15.6.1.3.2. Pharmacies

15.6.1.3.3. Urgent Care Centers

15.6.1.3.4. Research Institutes

15.6.1.3.5. Others

15.6.1.4. Saudi Arabia Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By Disorder Type

15.6.1.4.1. Major and Minor Depression

15.6.1.4.2. Obsessive Compulsive Disorder

15.6.1.4.3. Generalized Anxiety

15.6.1.4.4. Posttraumatic Stress (PTSD)

15.6.1.4.5. Social Anxiety

15.6.1.4.6. Agitation and Stress

15.6.1.4.7. Bipolar Disorder

15.6.1.4.8. Others

15.6.2. UAE

15.6.2.1. UAE Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By Type

15.6.2.1.1. Serotonin and Noradrenaline Reuptake Inhibitors (SNRIs)

15.6.2.1.2. Selective Serotonin Reuptake Inhibitors (SSRIs)

15.6.2.1.3. Tricyclic Antidepressants (TCAs)

15.6.2.1.4. Monoamine Oxidase Inhibitors (MAOIs)

15.6.2.1.5. Noradrenaline and Specific Serotoninergic Antidepressants (NaSSAs)

15.6.2.2. UAE Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By Mode of Administration

15.6.2.2.1. Tablets and Capsules

15.6.2.2.2. Liquids

15.6.2.2.3. Injections

15.6.2.2.4. Inhalation

15.6.2.2.5. Others

15.6.2.3. UAE Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By End-Users

15.6.2.3.1. Hospitals and Clinics

15.6.2.3.2. Pharmacies

15.6.2.3.3. Urgent Care Centers

15.6.2.3.4. Research Institutes

15.6.2.3.5. Others

15.6.2.4. UAE Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By Disorder Type

15.6.2.4.1. Major and Minor Depression

15.6.2.4.2. Obsessive Compulsive Disorder

15.6.2.4.3. Generalized Anxiety

15.6.2.4.4. Posttraumatic Stress (PTSD)

15.6.2.4.5. Social Anxiety

15.6.2.4.6. Agitation and Stress

15.6.2.4.7. Bipolar Disorder

15.6.2.4.8. Others

15.6.3. Egypt

15.6.3.1. Egypt Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By Type

15.6.3.1.1. Serotonin and Noradrenaline Reuptake Inhibitors (SNRIs)

15.6.3.1.2. Selective Serotonin Reuptake Inhibitors (SSRIs)

15.6.3.1.3. Tricyclic Antidepressants (TCAs)

15.6.3.1.4. Monoamine Oxidase Inhibitors (MAOIs)

15.6.3.1.5. Noradrenaline and Specific Serotoninergic Antidepressants (NaSSAs)

15.6.3.2. Egypt Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By Mode of Administration

15.6.3.2.1. Tablets and Capsules

15.6.3.2.2. Liquids

15.6.3.2.3. Injections

15.6.3.2.4. Inhalation

15.6.3.2.5. Others

15.6.3.3. Egypt Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By End-Users

15.6.3.3.1. Hospitals and Clinics

15.6.3.3.2. Pharmacies

15.6.3.3.3. Urgent Care Centers

15.6.3.3.4. Research Institutes

15.6.3.3.5. Others

15.6.3.4. Egypt Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By Disorder Type

15.6.3.4.1. Major and Minor Depression

15.6.3.4.2. Obsessive Compulsive Disorder

15.6.3.4.3. Generalized Anxiety

15.6.3.4.4. Posttraumatic Stress (PTSD)

15.6.3.4.5. Social Anxiety

15.6.3.4.6. Agitation and Stress

15.6.3.4.7. Bipolar Disorder

15.6.3.4.8. Others

15.6.4. Kuwait

15.6.4.1. Kuwait Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By Type

15.6.4.1.1. Serotonin and Noradrenaline Reuptake Inhibitors (SNRIs)

15.6.4.1.2. Selective Serotonin Reuptake Inhibitors (SSRIs)

15.6.4.1.3. Tricyclic Antidepressants (TCAs)

15.6.4.1.4. Monoamine Oxidase Inhibitors (MAOIs)

15.6.4.1.5. Noradrenaline and Specific Serotoninergic Antidepressants (NaSSAs)

15.6.4.2. Kuwait Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By Mode of Administration

15.6.4.2.1. Tablets and Capsules

15.6.4.2.2. Liquids

15.6.4.2.3. Injections

15.6.4.2.4. Inhalation

15.6.4.2.5. Others

15.6.4.3. Kuwait Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By End-Users

15.6.4.3.1. Hospitals and Clinics

15.6.4.3.2. Pharmacies

15.6.4.3.3. Urgent Care Centers

15.6.4.3.4. Research Institutes

15.6.4.3.5. Others

15.6.4.4. Kuwait Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By Disorder Type

15.6.4.4.1. Major and Minor Depression

15.6.4.4.2. Obsessive Compulsive Disorder

15.6.4.4.3. Generalized Anxiety

15.6.4.4.4. Posttraumatic Stress (PTSD)

15.6.4.4.5. Social Anxiety

15.6.4.4.6. Agitation and Stress

15.6.4.4.7. Bipolar Disorder

15.6.4.4.8. Others

15.6.5. South Africa

15.6.5.1. South Africa Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By Type

15.6.5.1.1. Serotonin and Noradrenaline Reuptake Inhibitors (SNRIs)

15.6.5.1.2. Selective Serotonin Reuptake Inhibitors (SSRIs)

15.6.5.1.3. Tricyclic Antidepressants (TCAs)

15.6.5.1.4. Monoamine Oxidase Inhibitors (MAOIs)

15.6.5.1.5. Noradrenaline and Specific Serotoninergic Antidepressants (NaSSAs)

15.6.5.2. South Africa Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By Mode of Administration

15.6.5.2.1. Tablets and Capsules

15.6.5.2.2. Liquids

15.6.5.2.3. Injections

15.6.5.2.4. Inhalation

15.6.5.2.5. Others

15.6.5.3. South Africa Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By End-Users

15.6.5.3.1. Hospitals and Clinics

15.6.5.3.2. Pharmacies

15.6.5.3.3. Urgent Care Centers

15.6.5.3.4. Research Institutes

15.6.5.3.5. Others

15.6.5.4. South Africa Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By Disorder Type

15.6.5.4.1. Major and Minor Depression

15.6.5.4.2. Obsessive Compulsive Disorder

15.6.5.4.3. Generalized Anxiety

15.6.5.4.4. Posttraumatic Stress (PTSD)

15.6.5.4.5. Social Anxiety

15.6.5.4.6. Agitation and Stress

15.6.5.4.7. Bipolar Disorder

15.6.5.4.8. Others

15.6.6. Rest of Middle East & Africa

15.6.6.1. Rest of Middle East & Africa Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By Type

15.6.6.1.1. Serotonin and Noradrenaline Reuptake Inhibitors (SNRIs)

15.6.6.1.2. Selective Serotonin Reuptake Inhibitors (SSRIs)

15.6.6.1.3. Tricyclic Antidepressants (TCAs)

15.6.6.1.4. Monoamine Oxidase Inhibitors (MAOIs)

15.6.6.1.5. Noradrenaline and Specific Serotoninergic Antidepressants (NaSSAs)

15.6.6.2. Rest of Middle East & Africa Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By Mode of Administration

15.6.6.2.1. Tablets and Capsules

15.6.6.2.2. Liquids

15.6.6.2.3. Injections

15.6.6.2.4. Inhalation

15.6.6.2.5. Others

15.6.6.3. Rest of Middle East & Africa Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By End-Users

15.6.6.3.1. Hospitals and Clinics

15.6.6.3.2. Pharmacies

15.6.6.3.3. Urgent Care Centers

15.6.6.3.4. Research Institutes

15.6.6.3.5. Others

15.6.6.4. Rest of Middle East & Africa Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By Disorder Type

15.6.6.4.1. Major and Minor Depression

15.6.6.4.2. Obsessive Compulsive Disorder

15.6.6.4.3. Generalized Anxiety

15.6.6.4.4. Posttraumatic Stress (PTSD)

15.6.6.4.5. Social Anxiety

15.6.6.4.6. Agitation and Stress

15.6.6.4.7. Bipolar Disorder

15.6.6.4.8. Others

15.7. Key Segment for Channeling Investments

15.7.1. By Country

15.7.2. By Type

15.7.3. By Mode of Administration

15.7.4. By End-Users

15.7.5. By Disorder Type

16. Latin America Antidepressant Drugs Market Analysis and Forecasts, 2020 - 2028

16.1. Overview

16.1.1. Latin America Antidepressant Drugs Market Revenue (US$ Mn)

16.2. Latin America Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By Type

16.2.1. Serotonin and Noradrenaline Reuptake Inhibitors (SNRIs)

16.2.2. Selective Serotonin Reuptake Inhibitors (SSRIs)

16.2.3. Tricyclic Antidepressants (TCAs)

16.2.4. Monoamine Oxidase Inhibitors (MAOIs)

16.2.5. Noradrenaline and Specific Serotoninergic Antidepressants (NaSSAs)

16.3. Latin America Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By Mode of Administration

16.3.1. Tablets and Capsules

16.3.2. Liquids

16.3.3. Injections

16.3.4. Inhalation

16.3.5. Others

16.4. Latin America Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By End-Users

16.4.1. Hospitals and Clinics

16.4.2. Pharmacies

16.4.3. Urgent Care Centers

16.4.4. Research Institutes

16.4.5. Others

16.5. Latin America Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By Disorder Type

16.5.1. Major and Minor Depression

16.5.2. Obsessive Compulsive Disorder

16.5.3. Generalized Anxiety

16.5.4. Posttraumatic Stress (PTSD)

16.5.5. Social Anxiety

16.5.6. Agitation and Stress

16.5.7. Bipolar Disorder

16.5.8. Others

16.6. Latin America Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By Country

16.6.1. Brazil

16.6.1.1. Brazil Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By Type

16.6.1.1.1. Serotonin and Noradrenaline Reuptake Inhibitors (SNRIs)

16.6.1.1.2. Selective Serotonin Reuptake Inhibitors (SSRIs)

16.6.1.1.3. Tricyclic Antidepressants (TCAs)

16.6.1.1.4. Monoamine Oxidase Inhibitors (MAOIs)

16.6.1.1.5. Noradrenaline and Specific Serotoninergic Antidepressants (NaSSAs)

16.6.1.2. Brazil Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By Mode of Administration

16.6.1.2.1. Tablets and Capsules

16.6.1.2.2. Liquids

16.6.1.2.3. Injections

16.6.1.2.4. Inhalation

16.6.1.2.5. Others

16.6.1.3. Brazil Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By End-Users

16.6.1.3.1. Hospitals and Clinics

16.6.1.3.2. Pharmacies

16.6.1.3.3. Urgent Care Centers

16.6.1.3.4. Research Institutes

16.6.1.3.5. Others

16.6.1.4. Brazil Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By Disorder Type

16.6.1.4.1. Major and Minor Depression

16.6.1.4.2. Obsessive Compulsive Disorder

16.6.1.4.3. Generalized Anxiety

16.6.1.4.4. Posttraumatic Stress (PTSD)

16.6.1.4.5. Social Anxiety

16.6.1.4.6. Agitation and Stress

16.6.1.4.7. Bipolar Disorder

16.6.1.4.8. Others

16.6.2. Argentina

16.6.2.1. Argentina Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By Type

16.6.2.1.1. Serotonin and Noradrenaline Reuptake Inhibitors (SNRIs)

16.6.2.1.2. Selective Serotonin Reuptake Inhibitors (SSRIs)

16.6.2.1.3. Tricyclic Antidepressants (TCAs)

16.6.2.1.4. Monoamine Oxidase Inhibitors (MAOIs)

16.6.2.1.5. Noradrenaline and Specific Serotoninergic Antidepressants (NaSSAs)

16.6.2.2. Argentina Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By Mode of Administration

16.6.2.2.1. Tablets and Capsules

16.6.2.2.2. Liquids

16.6.2.2.3. Injections

16.6.2.2.4. Inhalation

16.6.2.2.5. Others

16.6.2.3. Argentina Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By End-Users

16.6.2.3.1. Hospitals and Clinics

16.6.2.3.2. Pharmacies

16.6.2.3.3. Urgent Care Centers

16.6.2.3.4. Research Institutes

16.6.2.3.5. Others

16.6.2.4. Argentina Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By Disorder Type

16.6.2.4.1. Major and Minor Depression

16.6.2.4.2. Obsessive Compulsive Disorder

16.6.2.4.3. Generalized Anxiety

16.6.2.4.4. Posttraumatic Stress (PTSD)

16.6.2.4.5. Social Anxiety

16.6.2.4.6. Agitation and Stress

16.6.2.4.7. Bipolar Disorder

16.6.2.4.8. Others

16.6.3. Rest of Latin America

16.6.3.1. Rest of Latin America Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By Type

16.6.3.1.1. Serotonin and Noradrenaline Reuptake Inhibitors (SNRIs)

16.6.3.1.2. Selective Serotonin Reuptake Inhibitors (SSRIs)

16.6.3.1.3. Tricyclic Antidepressants (TCAs)

16.6.3.1.4. Monoamine Oxidase Inhibitors (MAOIs)

16.6.3.1.5. Noradrenaline and Specific Serotoninergic Antidepressants (NaSSAs)

16.6.3.2. Rest of Latin America Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By Mode of Administration

16.6.3.2.1. Tablets and Capsules

16.6.3.2.2. Liquids

16.6.3.2.3. Injections

16.6.3.2.4. Inhalation

16.6.3.2.5. Others

16.6.3.3. Rest of Latin America Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By End-Users

16.6.3.3.1. Hospitals and Clinics

16.6.3.3.2. Pharmacies

16.6.3.3.3. Urgent Care Centers

16.6.3.3.4. Research Institutes

16.6.3.3.5. Others

16.6.3.4. Rest of Latin America Antidepressant Drugs Market Revenue (US$ Mn) and Forecasts, By Disorder Type

16.6.3.4.1. Major and Minor Depression

16.6.3.4.2. Obsessive Compulsive Disorder

16.6.3.4.3. Generalized Anxiety

16.6.3.4.4. Posttraumatic Stress (PTSD)

16.6.3.4.5. Social Anxiety

16.6.3.4.6. Agitation and Stress

16.6.3.4.7. Bipolar Disorder

16.6.3.4.8. Others

16.7. Key Segment for Channeling Investments

16.7.1. By Country

16.7.2. By Type

16.7.3. By Mode of Administration

16.7.4. By End-Users

16.7.5. By Disorder Type

17. Competitive Benchmarking

17.1. Market Share Analysis, 2019

17.2. Global Presence and Growth Strategies

17.2.1. Mergers and Acquisitions

17.2.2. Product Launches

17.2.3. Investments Trends

17.2.4. R&D Initiatives

18. Player Profiles

18.1. Abbot

18.1.1. Company Details

18.1.2. Company Overview

18.1.3. Product Offerings

18.1.4. Key Developments

18.1.5. Financial Analysis

18.1.6. SWOT Analysis

18.1.7. Business Strategies

18.2. AbbVie

18.2.1. Company Details

18.2.2. Company Overview

18.2.3. Product Offerings

18.2.4. Key Developments

18.2.5. Financial Analysis

18.2.6. SWOT Analysis

18.2.7. Business Strategies

18.3. AstraZeneca

18.3.1. Company Details

18.3.2. Company Overview

18.3.3. Product Offerings

18.3.4. Key Developments

18.3.5. Financial Analysis

18.3.6. SWOT Analysis

18.3.7. Business Strategies

18.4. Eli Lilly and Company

18.4.1. Company Details

18.4.2. Company Overview

18.4.3. Product Offerings

18.4.4. Key Developments

18.4.5. Financial Analysis

18.4.6. SWOT Analysis

18.4.7. Business Strategies

18.5. F. Hoffmann-La Roche Ltd

18.5.1. Company Details

18.5.2. Company Overview

18.5.3. Product Offerings

18.5.4. Key Developments

18.5.5. Financial Analysis

18.5.6. SWOT Analysis

18.5.7. Business Strategies

18.6. GlaxoSmithKline plc.

18.6.1. Company Details

18.6.2. Company Overview

18.6.3. Product Offerings

18.6.4. Key Developments

18.6.5. Financial Analysis

18.6.6. SWOT Analysis

18.6.7. Business Strategies

18.7. H. Lundbeck A/S

18.7.1. Company Details

18.7.2. Company Overview

18.7.3. Product Offerings

18.7.4. Key Developments

18.7.5. Financial Analysis

18.7.6. SWOT Analysis

18.7.7. Business Strategies

18.8. Janssen Pharmaceuticals, Inc

18.8.1. Company Details

18.8.2. Company Overview

18.8.3. Product Offerings

18.8.4. Key Developments

18.8.5. Financial Analysis

18.8.6. SWOT Analysis

18.8.7. Business Strategies

18.9. Lupin Pharmaceuticals, Inc

18.9.1. Company Details

18.9.2. Company Overview

18.9.3. Product Offerings

18.9.4. Key Developments

18.9.5. Financial Analysis

18.9.6. SWOT Analysis

18.9.7. Business Strategies

18.10. Merck & Co., Inc.

18.10.1. Company Details

18.10.2. Company Overview

18.10.3. Product Offerings

18.10.4. Key Developments

18.10.5. Financial Analysis

18.10.6. SWOT Analysis

18.10.7. Business Strategies

18.11. Novartis AG

18.11.1. Company Details

18.11.2. Company Overview

18.11.3. Product Offerings

18.11.4. Key Developments

18.11.5. Financial Analysis

18.11.6. SWOT Analysis

18.11.7. Business Strategies

18.12. Pfizer Inc.

18.12.1. Company Details

18.12.2. Company Overview

18.12.3. Product Offerings

18.12.4. Key Developments

18.12.5. Financial Analysis

18.12.6. SWOT Analysis

18.12.7. Business Strategies

18.13. sanofi-aventis U.S. LLC

18.13.1. Company Details

18.13.2. Company Overview

18.13.3. Product Offerings

18.13.4. Key Developments

18.13.5. Financial Analysis

18.13.6. SWOT Analysis

18.13.7. Business Strategies

18.14. Sun Pharmaceutical Industries Ltd.

18.14.1. Company Details

18.14.2. Company Overview

18.14.3. Product Offerings

18.14.4. Key Developments

18.14.5. Financial Analysis

18.14.6. SWOT Analysis

18.14.7. Business Strategies

18.15. Takeda Pharmaceutical Company Limited

18.15.1. Company Details

18.15.2. Company Overview

18.15.3. Product Offerings

18.15.4. Key Developments

18.15.5. Financial Analysis

18.15.6. SWOT Analysis

18.15.7. Business Strategies

18.16. Teva Pharmaceutical Industries Ltd

18.16.1. Company Details

18.16.2. Company Overview

18.16.3. Product Offerings

18.16.4. Key Developments

18.16.5. Financial Analysis

18.16.6. SWOT Analysis

18.16.7. Business Strategies

18.17. Other Industry Participants

19. Key Findings

Note: This ToC is tentative and can be changed according to the research study conducted during the course of report completion.

**Exclusive for Multi-User and Enterprise User.

At Absolute Markets Insights, we are engaged in building both global as well as country specific reports. As a result, the approach taken for deriving the estimation and forecast for a specific country is a bit unique and different in comparison to the global research studies. In this case, we not only study the concerned market factors & trends prevailing in a particular country (from secondary research) but we also tend to calculate the actual market size & forecast from the revenue generated from the market participants involved in manufacturing or distributing the any concerned product. These companies can also be service providers. For analyzing any country specifically, we do consider the growth factors prevailing under the states/cities/county for the same. For instance, if we are analyzing an industry specific to United States, we primarily need to study about the states present under the same(where the product/service has the highest growth). Similar analysis will be followed by other countries. Our scope of the report changes with different markets.

Our research study is mainly implement through a mix of both secondary and primary research. Various sources such as industry magazines, trade journals, and government websites and trade associations are reviewed for gathering precise data. Primary interviews are conducted to validate the market size derived from secondary research. Industry experts, major manufacturers and distributors are contacted for further validation purpose on the current market penetration and growth trends.

Prominent participants in our primary research process include:

Key Opinion Leaders namely the CEOs, CSOs, VPs, purchasing managers, amongst others
Research and development participants, distributors/suppliers and subject matter experts

Secondary Research includes data extracted from paid data sources:

Reuters
Factiva
Bloomberg
One Source
Hoovers

Research Methodology

Key Inclusions

Request A Sample

Ask for Discount

Enquiry Before Buying

Request For Customization

Purchase Options

Single users $3300

Multi users $6600

Global users $7300

Buy Now

Reach to us

Call us on

+91-74002-42424

Drop us an email at

sales@absolutemarketsinsights.com